



Grifols successfully concludes the transition to its new intravenous immunoglobulin, Flebogamma DIF[®], in the United States

The new plant in Barcelona is the site of the manufacturing facilities for Flebogamma DIF[®] for the US market and will eventually take on production of this new generation product for Europe and other markets

Barcelona, November 22, 2007.- The new generation intravenous immunoglobulin IVIG was very well received in the United States and the transition was completed in record time (having begun in June 2007). The Flebogamma DIF[®] production plant in Barcelona, approved by the FDA in December 2006 and the EMEA in August 2007, will also manufacture this product for other markets once the regulatory processes are completed for each country. The company plans on completing the transition to Flebogamma DIF[®] on the European market, most likely beginning with Germany, in 18 months time.

Since the transition period in the United States has been completed and the manufacturing for this product has moved to the new plant, the company's first generation IVIG manufacturing plant has been freed up to focus its efforts once again on the European and Asian markets.

The company's recent investments and those planned through 2013 guarantee the product supply in the short and long term for both the first generation product (until it has been phased out in all the markets) and Flebogamma DIF[®]. The medium term investment plan includes financing for the construction of a second manufacturing plant for Flebogamma DIF[®] in Los Angeles, a replica of the one in Barcelona, which will begin operations in 2012.

About Grifols

Grifols is a holding company specialized in the pharmaceutical hospital sector and is present in more than 90 countries. Since May 2006, the company has been listed on the Spanish Stock Market and forms part of the IBEX Medium Cap index. Currently, it is the first company in Europe in the plasma derivatives sector and the fourth in production in the world. In terms of primary material, Grifols' plasma supply is ensured from its 77 plasmapheresis centres in the United States. The company's fractionation capacity at its plants in Barcelona (Spain) and Los Angeles (United States) will allow the company to respond to growing market demands. The company will strengthen its leadership in the industry as a vertically integrated company thanks to its existing investments and those planned for 2008-2012, totalling 400 million euros, which will allow the company to achieve sustained growth in the following 8-10 years.

GRIFOLS

For more information:

Raquel Lumbreras raquel_lumbreras@duomocomunicacion.com mobile: 659 57 21 85

Tristán Moreno-Torroba tristan_moreno@duomocomunicacion.com

Duomo Comunicación

Grifols Press Relations

Tel. +34 91 311 92 90/ Fax. +34 91 311 92 89